Jackson Eye Now Offers the First and Only FDA-Approved Cross-linking Therapy for the Treatment of Progressive Keratoconus
"Corneal cross-linking is beneficial to my patients in that if offers them a therapeutic option to limit the progression of keratoconus," says Dr. Mitchel Jackson. "The FDA approval of corneal cross-linking with Photrexa products and the KXL System offers new treatment options for appropriate patients who, until now, had few options to help with their vision challenges and no therapeutic treatment for this sight-threatening condition," said Mitchell Jackson, M.D.
In keratoconus patients, the typically round, dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge that produces optical irregularities that affect vision. A rare condition, keratoconus typically appears in individuals who are in their late teens or early twenties. Early symptoms include blurring or distortion of vision or increased sensitivity to light.
Corneal cross-linking using Avedro's Photrexa products and KXL System is a medical procedure that combines the use of ultra-violet (UV) light and riboflavin (vitamin B2) eye drops. The procedure works by creating new corneal collagen cross-links, which results in a shortening and thickening of collagen fibrils that leads to the stiffening the cornea. Cross-linking, which has been performed in Europe since 2003, is considered the standard of care around the world for keratoconus.
"Early diagnosis is critical and allows patients to be treated at the onset of the disease.," added Dr. Jackson "Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."
To determine if corneal cross-linking may be right for them, patients can contact Jackson Eye at 847-356-0700; www.myjacksoneye.com.
What are Photrexa Viscous and Photrexa?
PHOTREXA VISCOUS and PHOTREXA are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus.
Important Safety Information
For more information, click here for full Prescribing Information or ask your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
About Mitchell A. Jackson, M.D.
Dr. Mitchell Jackson is a board-certified ophthalmologist specializing in cataract and refractive surgery. He received his medical degree from Chicago Medical School, completed his internship at Columbus Hospital and his Ophthalmology residency at University of Chicago Hospitals. Currently, Dr. Jackson is the Founder/Medical Director of Jacksoneye and is also a clinical assistant at the University of Chicago Hospitals.
Contact:
Brisa Vargas
Jackson Eye
847-356-0700
BRISA@myjacksoneye.com